PTC Therapeutics, Inc. Repayments of Long-Term Debt
PTC Therapeutics, Inc. (PTCT) reported Repayments of Long-Term Debt of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-16.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2017-03-16
- PTC Therapeutics, Inc. repayments of long-term debt for the quarter ending 2014-12-31 was $0.00, a 100.00% decline year-over-year.
- PTC Therapeutics, Inc. repayments of long-term debt for the quarter ending 2014-09-30 was $0.00, a 100.00% decline year-over-year.
- PTC Therapeutics, Inc. repayments of long-term debt for the quarter ending 2014-06-30 was $12.00K, a 98.91% decline year-over-year.
- PTC Therapeutics, Inc. repayments of long-term debt for the quarter ending 2014-03-31 was $37.00K, a 96.54% decline year-over-year.
- PTC Therapeutics, Inc. repayments of long-term debt for fiscal 2016 was $0.00.
- PTC Therapeutics, Inc. repayments of long-term debt for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
- PTC Therapeutics, Inc. repayments of long-term debt for fiscal 2014 was $49.00K, a 99.02% decline from fiscal 2013.
- PTC Therapeutics, Inc. repayments of long-term debt for fiscal 2013 was $5.00M, a 28.05% decline from fiscal 2012.
| Period end | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 6 month as first filed | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 9 month as first filed | Repayments of Long-term Debt 12 month | Repayments of Long-term Debt 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-03-16 | ||||||
| 2015-12-31 | $0.00 10-K · filed 2017-03-16 | ||||||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $0.00 derived: sum of 2 quarters · filed 2017-03-16 | $12.00K derived: sum of 3 quarters · filed 2017-03-16 | $49.00K 10-K · filed 2017-03-16 | |||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $12.00K derived: sum of 2 quarters · filed 2015-11-09 | $49.00K 10-Q · filed 2015-11-09 | $85.00K derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-06-30 | $12.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-31 | $49.00K 10-Q · filed 2015-07-31 | $85.00K derived: sum of 3 quarters · filed 2016-02-29 | $2.87M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-03-31 | $37.00K 10-Q · filed 2015-05-05 | $73.00K derived: sum of 2 quarters · filed 2016-02-29 | $2.86M derived: sum of 3 quarters · filed 2016-02-29 | $3.96M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2013-12-31 | $36.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $2.82M derived: sum of 2 quarters · filed 2016-02-29 | $3.93M derived: sum of 3 quarters · filed 2016-02-29 | $5.00M 10-K · filed 2016-02-29 | $5.00M 10-K · filed 2014-03-06 | ||
| 2013-09-30 | $2.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $3.89M derived: sum of 2 quarters · filed 2014-11-06 | $4.96M 10-Q · filed 2014-11-06 | $4.96M 10-Q · filed 2013-11-14 | $5.66M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2013-06-30 | $1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $2.17M 10-Q · filed 2014-08-07 | $2.17M 10-Q · filed 2013-08-13 | $2.88M derived: sum of 3 quarters · filed 2015-03-02 | $4.38M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2013-03-31 | $1.07M 10-Q · filed 2014-05-06 | $1.77M derived: sum of 2 quarters · filed 2015-03-02 | $3.27M derived: sum of 3 quarters · filed 2015-03-02 | ||||
| 2012-12-31 | $703.88K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $2.20M derived: sum of 2 quarters · filed 2015-03-02 | $6.94M 10-K · filed 2015-03-02 | $6.94M 10-K · filed 2014-03-06 | |||
| 2012-09-30 | $1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | $6.24M 10-Q · filed 2013-11-14 | |||||
| 2012-06-30 | $4.74M 10-Q · filed 2013-08-13 | ||||||
| 2011-12-31 | $7.19M 10-K · filed 2014-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |